The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2013-03-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-12-0998PMID 23493311PMCID PMC3681857
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

  2015cited by this paper
• Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).

  2012influential reference
• The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.

  2012cited by this paper
• A phase I dose-escalation study of the HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs).

  2012cited by this paper
• PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

  2012cited by this paper
• Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.

  2012cited by this paper
• Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer

  2012cited by this paper
• 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

  2011cited by this paper
• c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

  2011cited by this paper
• Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.

  2011cited by this paper
• Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

  2011cited by this paper
• An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

  2011cited by this paper
• Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

  2010cited by this paper
• Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800

  2010cited by this paper
• Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines

  2010cited by this paper
• Genetic Determinants of Pemetrexed Responsiveness and Nonresponsiveness in Non-small Cell Lung Cancer Cells

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Predictors of competing mortality in advanced head and neck cancer.

  2010cited by this paper
• AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.

  2010cited by this paper
• Death by chaperone: HSP90, HSP70 or both?

  2009cited by this paper
• Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential Target

  2008cited by this paper
• Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

  2008cited by this paper
• Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial

  2008cited by this paper
• A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

  2008cited by this paper
• X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility

  2008cited by this paper
• NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

  2008cited by this paper
• Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

  2008influential reference
• Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.

  2008cited by this paper
• NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

  2008cited by this paper
• Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.

  2007cited by this paper
• Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro

  2007cited by this paper
• Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Establishment and characterization of two breast cancer xenografts in immunodeficient mice for studies on hormone-dependent and hormone-independent tumor growth, progression and invasion

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005influential reference
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005cited by this paper
• Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

  2005cited by this paper
• Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

  2005cited by this paper
• Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.

  2005cited by this paper
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper
• Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas

  2005cited by this paper
• Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

  2004cited by this paper
• Aha1 Binds to the Middle Domain of Hsp90, Contributes to Client Protein Activation, and Stimulates the ATPase Activity of the Molecular Chaperone*

  2003cited by this paper
• PANTHER: a browsable database of gene products organized by biological function, using curated protein family and subfamily classification

  2003cited by this paper
• Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.

  2003cited by this paper
• Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

  2002cited by this paper
• Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by a bidirectional promoter

  2002cited by this paper
• Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function*

  2002cited by this paper
• Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone

  2000cited by this paper

• AutoEdge-CCP: A novel approach for predicting cancer-associated circRNAs and drugs based on automated edge embedding

  2024cites this paper
• Targeting HSP90 in Gynecologic Cancer: Molecular Mechanisms and Therapeutic Approaches

  2024cites this paper
• Prognosis and personalized treatment prediction in lung adenocarcinoma: An in silico and in vitro strategy adopting cuproptosis related lncRNA towards precision oncology

  2023cites this paper
• Benzo(a)pyrene regulates chaperone-mediated autophagy via heat shock protein 90

  2022cites this paper
• Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.

  2022cites this paper
• Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance

  2022cites this paper
• Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro

  2021cites this paper
• Analysis of Genome-Wide Alternative Splicing Profiling and Development of Potential Drugs in Lung Adenocarcinoma

  2021cites this paper
• Understanding the Hsp90 N-Terminal Dynamics: Structural and Molecular Insights into the Therapeutic Activities of Anticancer Inhibitors Radicicol (RD) and Radicicol Derivative (NVP-YUA922)

  2020cites this paper
• Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.

  2020cites this paper
• Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.

  2020cites this paper
• Suppression of Esophageal Cancer Stem-like Cells by SNX-2112 Is Enhanced by STAT3 Silencing

  2020cites this paper
• Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.

  2019cites this paper
• A Review on the Antitumor Activity of Various Nitrogenous-based Heterocyclic Compounds as NSCLC Inhibitors.

  2019cites this paper
• Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines.

  2019cites this paper
• Heat Shock Protein 90 Inhibitors in Lung Cancer Therapy

  2019cites this paper
• Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants

  2018cites this paper
• EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

  2018cites this paper
• Expedient Access to 2-Benzazepines by Palladium-Catalyzed C-H Activation: Identification of a Unique Hsp90 Inhibitor Scaffold.

  2018cites this paper
• The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

  2018cites this paper
• HSP90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC

  2018cites this paper
• Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants *

  2018cites this paper
• HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome

  2018cites this paper
• HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients

  2017cites this paper
• HECTD 3 Mediates an HSP 90-Dependent Degradation Pathway for Protein Kinase Clients Graphical

  2017cites this paper
• Targeting cancer cell mitochondria as a therapeutic approach: recent updates.

  2017cites this paper
• Re-examining HSPC1 inhibitors

  2017cites this paper
• Molecular mechanism and targeted therapy of Hsp90 involved in lung cancer: New discoveries and developments (Review).

  2017cites this paper
• Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold.

  2016cites this paper
• HSP90 inhibitors in lung cancer: promise still unfulfilled.

  2016cites this paper
• Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib

  2016cites this paper
• Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922

  2016cites this paper
• TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

  2016cites this paper
• Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition

  2016cites this paper
• Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

  2016cites this paper
• Natural Product Inspired N‐Terminal Hsp90 Inhibitors: From Bench to Bedside?

  2016cites this paper
• Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner

  2016cites this paper
• The novel HSP90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo.

  2016cites this paper
• The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

  2016cites this paper
• Targeting Hsp90 in Non-Cancerous Maladies.

  2016cites this paper
• Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.

  2016cites this paper
• Heat Shock Protein Inhibitors: Success Stories

  2016cites this paper
• Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

  2015cites this paper
• Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90

  2015cites this paper
• Synthesis and Evaluation of a Novel Deguelin Derivative , L 80 , which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90

  2015cites this paper
• Biodegradable Hybrid Nanogels for Combination Chemotherapy

  2015cites this paper
• HGUE-C-1 is an atypical and novel colon carcinoma cell line

  2015cites this paper
• Destabilizing RET in targeted treatment of thyroid cancers

  2015cites this paper
• Inhibición de hsp90 como nueva estrategia antitumoral contra el cáncer de páncreas exocrino y el cáncer de colon y recto

  2015influential citation
• Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

  2015cites this paper
• The Effect of Structure and Mechanism of the Hsp70 Chaperone on the Ability to Identify Chemical Modulators and Therapeutics

  2015cites this paper
• ALK阳性非小细胞肺癌患者克唑替尼耐药的机制和治疗措施

  2015cites this paper
• HSP90 Inhibitor-Based Strategies for Cancer Therapy: Advancing Toward Clinical Impact

  2015cites this paper
• Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma

  2015influential citation
• EGFR Inhibitors in Treatment of Lung Adenocarcinoma

  2014cites this paper
• Nematode Hsp90: highly conserved but functionally diverse

  2014cites this paper
• Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells.

  2014cites this paper
• Primary cilium-associated genes mediate bone marrow stromal cell response to hypoxia.

  2014cites this paper
• Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.

  2014cites this paper
• Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?1

  2014cites this paper
• Heat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia–lymphoma cells

  2014cites this paper
• Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

  2014cites this paper
• Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

  2014cites this paper
• A Repurposing Strategy for Hsp90 Inhibitors Demonstrates Their Potency against Filarial Nematodes

  2014cites this paper
• Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses

  2014influential citation
• Molecular pathways and therapeutic targets in lung cancer

  2014cites this paper
• 非小细胞肺癌T790M基因突变研究进展

  2013cites this paper
• Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation

  2013cites this paper
• Studies of targeted treatment in RET mutant thyroid cancers

  2013cites this paper
• Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.

  2013cites this paper